List view / Grid view
15 January 2019 | By Douglas J. Swirsky
Immunotherapy and targeted treatments, including targeted chemotherapy, continue to show great potential in cancer care. Future steps in their development will involve improving their ability to treat a wider range of cancers and a broader cross-section of the patient population, especially those for whom current treatments have shown limited efficacy...
11 December 2018 | By Matthias Nees and Malin Åkerfelt (University of Turku - Finland)
Drug discovery is still hampered by the routine use of cell-based models that often fail to recapitulate the truly relevant biological complexity of the corresponding disease. Just moving from two- (2D) towards three-dimensional (3D) cell culture model systems like spheroids and organoids is not enough to generate truly representative and…
10 December 2018 | By Christopher J. Langmead
G protein-coupled receptors (GPCRs) are seven transmembrane spanning proteins that mediate the physiological responses to a broad array of stimuli, including photons, biogenic amines, peptides and large proteins. They represent the target of approximately one-third of all approved drugs,1 yet paradoxically remain a relatively under-exploited protein class.
10 December 2018 | By Anowarul Amin
In the wake of the human genome project, molecular biology and genetic technologies are tremendously integrating into biomedical research. Currently, PCR, qPCR, and sequencing are key tools in the clinical laboratory for the detection and characterisation of microorganisms and genetic disorders.
10 December 2018 | By NanoTemper Technologies
This webinar, held on 25 October 2018, presented the results from integrated fragment-based approaches for Indoleamine 2,3 dioxygenase 1 (IDO1), an enzyme widely recognised as a drug target for the development of immunotherapeutic small molecules in oncology, unveiling the first ligands able to modulate non-catalytic signalling.
7 December 2018 | By Pushpanathan Muthuirulan
The catastrophic consequences of ever-increasing rates of death from infectious diseases demands new experimental strategies for drug target selection and drug design. Over the last decade, the pharmaceutical industry has been wounded by several issues including failure of drug-development programmes, burgeoning cost of drug development, increasing regulatory control, lack of…
7 December 2018 | By PerkinElmer
Harmonising drug-target binding data analytics looks at building a single, integrated software platform for a future pharma research and development digital ecosystem. This webinar, sponsored by PerkinElmer, outlined the fundamentals of a design process where an experimental analytics data workflow was integrated into a more seamlessly interactive digital platform.
7 December 2018 | By Bio-Techne
The webinar presented an overview of the pre-clinical milestones, the current status of the global drug pipeline and a description of a number of novel drugs undergoing clinical trials.
6 December 2018 | By Leena Mol Thuruthippalli (Senior Product Manager – Protein & Cell Analysis at Thermo Fisher Scientific)
Three-dimensional cell cultures (spheroids, organoids) are becoming widely used as a new predictive tool in early drug discovery. The use of 3D cell cultures is believed to provide a more physiologically relevant response than monolayer (2D) cell cultures because they closely mimic the extracellular matrix and cell-cell interactions that occur…
6 December 2018 | By Steven Jarvis (Scientific Director - Global Strategic Accounts at Merck)
The basic premise of drug discovery screening necessitates that the biological assays upon which it depends can be performed in a reproducible manner. In addition, the techniques employed must generate results that are biologically relevant and actionable.
5 December 2018 | By BMG Labtech GmbH
The Small Molecule Screening Facility (SMSF) at the University of Wisconsin Madison is a comprehensive high-throughput screening (HTS) centre where researchers have investigated antibiotic-resistant bacterial infections and screening for protein-protein interactions using HTS methods.
5 December 2018 | By Michael Kowalski (Global Project Manager at Beckman Coulter)
For drug discovery and biomarker research, screening campaigns are employed to identify potential new treatments for diseases and to answer questions that remain unknown in the scientific community.
4 December 2018 | By Stephen J. Capuzzi and David C. Morris (Eshelman School of Pharmacy - University of North Carolina Chapel Hill)
High-throughput screening (HTS) technologies have enabled the routine testing of millions of compounds towards the identification of novel ‘hit’ molecules for therapeutic targets. Oftentimes in this drug discovery process, however, compounds that show promising activity in primary screens show no activity during subsequent hit qualification or progression efforts.
4 December 2018 | By Drug Target Review
Researchers are always looking more effective and efficient ways of making their work more successful. In this supplement, some of our commercial partners share their data, detailing the application of their technology.
4 December 2018 | By PerkinElmer
Data integrity and computerised system validations (CSV) have become an area of increased scrutiny for regulatory agencies over the last several years. Understanding how the agencies view data integrity is critical for laboratories to maintain complete compliance.
Follow: